MetaCap

Helus Pharma Inc. (HELP)

NASDAQ: HELPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.11-0.67 (-9.88%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HELP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$487.68M
EPS (TTM)
-$4.25
52-week range
3.76 – 15.15
Day range
6.05 – 6.73
Volume / Avg
2.50M / 1.83M
Beta
—

52-week range

$3.76$15.15

HELP stock today

Helus Pharma (HELP) closed at $6.11 on Nov 20, down 9.88% (-$0.67), versus the S&P 500's 3.70% decline. Shares are 59.7% below their 52-week high of $15.15, set on Sep 18, 2026 and 62.5% above the 52-week low of $3.76, in the middle of the past year's range. HELP is down 25.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 9.3%.

Helus Pharma has posted a net loss over the last twelve months (EPS of -$4.25), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Helus Pharma

Company profile

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Michael I. Halstead J.D.
Headquarters
Toronto, ON
Employees
100
Website
helus.com

Analyst forecast

Forecast

Consensus (11 analysts)

none

Avg. price target

$40.62+564.81%

  • Strong buy 1
  • Buy 10
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $14.86High $69.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-1.41 vs $-0.67
Surprise
-110.45%

HELP news

All HELP news

Helus Pharma peers

Health Care sector
HELP peer companies
CompanyPrice% ChgMarket capCompare
WVEWave Life Sciences Inc.2.56-5.88%$504.91Mvs HELP
EVOEvotec SE ADR1.32-8.97%$469.11Mvs HELP
MNPRMonopar Therapeutics Inc.69.00-1.84%$467.60Mvs HELP
RZLTRezolute Inc.3.92-6.67%$465.58Mvs HELP
ALMSAlumis Inc.3.96-8.54%$514.09Mvs HELP
BLSMBlossomHill Therapeutics Inc.14.51+0.69%$461.20Mvs HELP
GYREGyre Therapeutics Inc.4.21-6.86%$460.79Mvs HELP
NGNENeurogene Inc.22.15-3.40%$458.53Mvs HELP

Indexes, lists and sector

Helus Pharma stock FAQ

What is Helus Pharma's stock price today?

HELP last traded at $6.11 as of Nov 20, 4:00 PM EST, down 9.88% on the day. Prices are delayed at least 15 minutes.

Does Helus Pharma pay a dividend?

No. Helus Pharma does not currently pay a regular cash dividend.

Who is Helus Pharma's CEO?

Mr. Michael I. Halstead J.D. is the chief executive officer of Helus Pharma Inc., which has about 100 employees.

Has HELP ever split its stock?

Yes. The most recent HELP stock split was a 1-for-38 split on Sep 19, 2024, one of 2 splits on record.

What is the HELP 52-week high?

The 52-week high for HELP is $15.15 and the 52-week low is $3.76. The stock is currently 59.7% below its high.

Compare HELP